Gerald Linette
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (10)
Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse events of grade 3-4. (7) Cytokine release syndrome and ICANS. (8). Maintenance therapy. Supplemental Figures: (1) Study schematic and subject disposition, (2) Correlates of manufacturing success, (3) Hematopoietic recovery, (4) Post-infusion T cell phenotypes, (5) Correlates of in vivo expansion and manufacturing success, (6) Late post-infusion CAR T cell re-expansion, (7) Soluble BCMA, (8) Late-onset clinical responses, (9) MM cell BCMA expression, (10) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA monotherapy patients, (11) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA + huCART19 combination therapy patients, (12) Sustained post-treatment SOX2-specific T-cell responses.
Year:
2025
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding to first-line therapy (phase B, N = 20), followed by early lenalidomide or pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance of low-grade neurologic toxicity. Among 15 subjects with measurable disease, 10 exhibited partial response (PR) or better; among 26 subjects responding to prior therapy, 9 improved their response category and 4 converted to minimal residual disease (MRD)–negative complete response/stringent complete response. Early maintenance therapy was safe, feasible, and coincided in some patients with CAR T-cell reexpansion and late-onset, durable clinical response. Outcomes with CART-BCMA + huCART19 were similar to CART-BCMA alone. Collectively, our results demonstrate favorable safety, pharmacokinetics, and antimyeloma activity of dual-target CAR T-cell therapy in early lines of MM treatment. Significance: CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety, pharmacokinetics, and efficacy of CAR T cells in patients with low disease burden, responding to current therapy, combined with standard maintenance therapy. This article is highlighted in the In This Issue feature, p. 101
Year:
2025
A, Expansion of T cells in which stimulation cultures did or did not contain IL7/IL15. B, CD4 and CD8 composition of and C, memory composition of T cell products at the conclusion of manufacturing when stimulation cultures did or did not include IL7/IL15.
Year:
2024
A, Representative ow cytometry plots of transduction efficiency of various synthetic receptors in control (unedited) and TRAC+TRBCKO T cells when editing is performed pre-stimulation. B, Stability of CRISPR editing over-time when performing post-stimulation editing.
Year:
2024
A, Expansion of T cells in which stimulation cultures did or did not contain IL7/IL15. B, CD4 and CD8 composition of and C, memory composition of T cell products at the conclusion of manufacturing when stimulation cultures did or did not include IL7/IL15.
Year:
2024
Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T lymphocytes, leading to the development of practice changing therapies for patients with cancer and the promise of synthetic immune cell therapies for a variety of nonmalignant diseases. Many distinct conceptual and technical approaches have been used to edit T-cell genomes, however targeted assessments of which techniques are most effective for manufacturing, gene editing, and transgene expression are rarely reported. Through extensive comparative evaluation, we identified methods that most effectively enhance engineering of research-scale and preclinical T-cell products at critical stages of manufacturing.
Year:
2024
A, Representative ow cytometry plots of transduction efficiency of various synthetic receptors in control (unedited) and TRAC+TRBCKO T cells when editing is performed pre-stimulation. B, Stability of CRISPR editing over-time when performing post-stimulation editing.
Year:
2024
Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T lymphocytes, leading to the development of practice changing therapies for patients with cancer and the promise of synthetic immune cell therapies for a variety of nonmalignant diseases. Many distinct conceptual and technical approaches have been used to edit T-cell genomes, however targeted assessments of which techniques are most effective for manufacturing, gene editing, and transgene expression are rarely reported. Through extensive comparative evaluation, we identified methods that most effectively enhance engineering of research-scale and preclinical T-cell products at critical stages of manufacturing.
Year:
2024
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.
Year:
2024
Genome editing technologies have seen remarkable progress in recent years, enabling precise regulation of exogenous and endogenous genes. These advances have been extensively applied to the engineering of human T lymphocytes, leading to the development of practice changing therapies for patients with cancer and the promise of synthetic immune cell therapies for a variety of nonmalignant diseases. Many distinct conceptual and technical approaches have been used to edit T-cell genomes, however targeted assessments of which techniques are most effective for manufacturing, gene editing, and transgene expression are rarely reported. Through extensive comparative evaluation, we identified methods that most effectively enhance engineering of research-scale and preclinical T-cell products at critical stages of manufacturing.
Year:
2024
Collaborators (21)
Alfred Garfall
Assistant Professor, Clinician-Educator
University of Pennsylvania
Edward A. Stadtmauer
University of Pennsylvania
Stefan Barta
Academic Clinician Associate Professor
University of Pennsylvania
Dan Vogl
Associate Professor of Medicine
University of Pennsylvania
Saar I. Gill
University of Pennsylvania
Elizabeth Hexner
Associate Professor, Clinician-Educator
University of Pennsylvania
Daniel J. Powell
Associate Professor
University of Pennsylvania
Carl H. June
Professor
University of Pennsylvania
Joseph A. Fraietta
University of Pennsylvania
Mohamed Abdel-Mohsen
Associate Professor
Northwestern University
Nathan Singh
Assistant Professor
Washington University School of Medicine
Stefano Pileri
Direttore della Ematopatologia
European Institute of Oncology
David Teachey
Professor
Children's Hospital of Philadelphia
Antonia Rotolo
Imperial College London
Adam Snook
Professor
Thomas Jefferson University
sandra susanibar adaniya
Assistant Professor
University of Pennsylvania
Stephen Schuster
Professor, Clinician-Educator
Hospital of the University of Pennsylvania
Beatriz M. Carreno
University of Pennsylvania
Marco Ruella
PI
University of Pennsylvania
Michael Milone
Associate Professor
University of Pennsylvania
Adam Cohen
Associate Professor, Clinician-Educator
University of Pennsylvania
Make your next move.
Prepare your application
Review drafts before you send them.